|
Sometimes a breakthrough therapeutic solution is simply a new way of administering an existing medication that makes it more convenient, more effective, or even taste better. What may seem like a small change in the way a drug can be administered generally has a large-scale impact on the way millions of patients comply with treatment regimens.
Cephalon knows that exploring ways to make existing medicines even better is best for patients. The value these new technologies can bring — greater bioavailability, enhanced absorption, faster onset of action and more efficient dosing — can transform the patient experience as profoundly as a completely new product. For some patients, a new delivery technology makes taking medication easier; for others, it makes taking medication possible.
The Cephalon drug delivery technologies interface is managed by its wholly owned subsidiary CIMA LABS (www.cimalabs.com). CIMA LABS offers pharmaceutical partners a portfolio of commercialized technologies for prescription and over-the-counter medications. In addition to proven technologies, CIMA LABS is making investments in new areas to provide more choices in drug delivery.
|